Nimustine

Nimustine (INN) is a nitrosourea alkylating agent.[1]

Nimustine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • N'-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-(2-chloroethyl)-N-nitrosourea
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.050.744
Chemical and physical data
FormulaC9H13ClN6O2
Molar mass272.69 g·mol−1
3D model (JSmol)
SMILES
  • CC1=NC=C(C(=N1)N)CNC(=O)N(CCCl)N=O
InChI
  • InChI=1S/C9H13ClN6O2/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14) N
  • Key:VFEDRRNHLBGPNN-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

It is used to treat malignant brain tumors and has proven to be rather effective.[2][3]

References

  1. "NCI Drug Dictionary". National Cancer Institute. Retrieved 2019-03-17.
  2. CHEBI:75270 - nimustine
  3. Endo T, Inoue T, Sugiyama S, Saito R, Tominaga T (April 2020). "Regression of Recurrent Spinal Cord High-Grade Glioma After Convection-Enhanced Delivery of Nimustine Hydrochloride: Case Reports and Literature Review". Operative Neurosurgery (Hagerstown, Md.). 18 (4): 451–459. doi:10.1093/ons/opz172. PMID 31414134.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.